bioRxiv · 10.1101/2021.05.19.444889
An AAV-ie based Vaccine effectively protects against SARS-CoV-2 and Circulating Variants
Abstract
Prophylactic vaccines against SARS-CoV-2 have been extensively developed globally to overcome the COVID-19 pandemic. However, recently emerging SARS-CoV-2 variants B.1.1.7 and B.1.351 limit the vaccine protection effects and successfully escape antibody cocktail treatment. Herein, based on our previously engineered adeno-associated viral (AAV) vector, AAV-ie, and systematic immunogen screening, we developed an AAV-ie-S1 vaccine with thermostability, high efficiency, safety, and single-dose vaccination advantage. Importantly, the AAV-ie-S1 immune sera efficiently neutralize B.1.1.7 and B.1.351, indicating a potential to circumvent the spreading of SARS-CoV-2.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Zhao, S., Tan, F., Ke, J., Yang, J., Lin, C.-b., Wang, H., zhong, g.. 2021-05-20. An AAV-ie based Vaccine effectively protects against SARS-CoV-2 and Circulating Variants. https://doi.org/10.1101/2021.05.19.444889
Cite the original work for its findings. Save a collection to share your selection of sources.